Pharmascroll Research and Consulting Pvt Ltd is a single-minded analytical team that specializes in consulting services across the global healthcare sector.
The core area of their activity is the research of the pharmaceutical industries, in particular, the medications for the widespread chronic illnesses. Medical specialists and pharmacologists can request all types of research on the issues concerning their business. The outcome of the Pharmascroll’s team is a comprehensive analysis of the latest indications together with succinct information analysis product.
Pharmascroll’s reports contain logical conclusions, reliable data, and viable solutions. Depending on the customer’s objectives, the research can be primary, secondary or combined.
The experts meticulously study credible information sources such as:
- Scientific journals
- Industry publications
- Manufacturers’ offerings
- Product portfolios
- Financial surveys
- News items
- Investment insights
The company’s specialists qualified in the management, pharmaceutical, and statistical areas conduct the research to gather intelligence to ensure the client’s business growth in the industry.
Publications found:
66
Sort by:
PPMS- Disease Overview
US$ 1,000.00
Detailed overview of PPMS disease area including its definition, etiology, symptoms and disease diagnosis
September 2017
20 pages
PPMS- Disease Overview and Epidemiology
US$ 2,000.00
Overview of Primary progressive multiple sclerosis disease indication in detail and PPMS epidemiology in the present scenario and in future (forecasted) as well in the key geographies across the globe.
September 2017
27 pages
PPMS- Disease Overview, Epidemiology and Drug Overview
US$ 3,000.00
Report gives the overview of Primary progressive multiple sclerosis disease indication in detail, highlights the PPMS epidemiology in the present scenario and in future (forecasted) as well in the ... globe and elaborates on the drugs prescribed and expected to be prescribed in PPMS by the physicians.
September 2017
62 pages
PPMS- A Detailed Overview
US$ 5,000.00
The report gives the overview of Primary progressive multiple sclerosis disease indication in detail, highlights the PPMS epidemiology in the key geographies, elaborates on ... the drugs prescribed and expected to be prescribed in PPMS and covers the detailed market sizing drug wise and country wise in value ...
September 2017
103 pages
PPMS- France Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in France market, highlights the PPMS epidemiology in France, elaborates on ... final part of the report gives a detailed overview of PPMS market sizing drug wise in France both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Germany Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Germany market, highlights the PPMS epidemiology in Germany, elaborates on ... final part of the report gives a detailed overview of PPMS market sizing drug wise in Germany both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Italy Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Italy market, highlights the PPMS epidemiology in Italy, elaborates on ... The final part of the report gives a detailed overview of PPMS market sizing drug wise in Italy both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Spain Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Spain market, highlights the PPMS epidemiology in Spain, elaborates on ... The final part of the report gives a detailed overview of PPMS market sizing drug wise in Spain both in terms of value sales and patient ...
September 2017
73 pages
PPMS- UK Overview
US$ 3,000.00
... . The report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in UK market, highlights the PPMS epidemiology in UK, elaborates on ... forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise in UK both in terms of value sales ...
September 2017
73 pages
PPMS- US Overview
US$ 3,000.00
... The report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in the US market, highlights the PPMS epidemiology in the US, ... progressive forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise in the US both in terms of value ...
September 2017
73 pages
SPMS- France Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in France market, highlights the SPMS epidemiology in France, elaborates on ... final part of the report gives a detailed overview of SPMS market sizing drug wise in France both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Germany Overview
US$ 3,000.00
... gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Germany market, highlights the SPMS epidemiology in Germany, elaborates on ... final part of the report gives a detailed overview of SPMS market sizing drug wise in Germany both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Italy Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Italy market, highlights the SPMS epidemiology in Italy, elaborates on ... The final part of the report gives a detailed overview of SPMS market sizing drug wise in Italy both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Spain Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Spain market, highlights the SPMS epidemiology in Spain, elaborates on ... The final part of the report gives a detailed overview of SPMS market sizing drug wise in Spain both in terms of value sales and patient ...
September 2017
78 pages
SPMS- UK Overview
US$ 3,000.00
... . The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in UK market, highlights the SPMS epidemiology in UK, elaborates on ... forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in UK both in terms of value sales ...
September 2017
78 pages
SPMS- US Overview
US$ 3,000.00
... The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in the US market, highlights the SPMS epidemiology in the US, ... progressive forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in the US both in terms of value ...
September 2017
78 pages